---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-068745"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:44:54.808030+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio to publish video with additional Phase 2 XPro trial findings after AAIC

## Summary
- Video detailing additional MINDFuL Phase 2 findings of XPro (soluble TNF inhibitor) to be published July 31 at 4 PM ET.
- Trial showed consistent cognitive and biomarker benefit after 6 months in amyloid-beta+ patients with ≥2 inflammatory blood biomarkers.
- Data presented at AAIC July 29 in Toronto; corporate presentation also filed as Exhibit 99.2.
- Dr. Sharon Cohen presented; VP Dr. CJ Barnum cited meaningful changes in short trial.

## SEC filing metadata
- accession: 0001213900-25-068745
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025068745/0001213900-25-068745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025068745/ea0250594-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-068745
- JSON: https://secwatch.observer/filing/0001213900-25-068745.json
- Plain text: https://secwatch.observer/filing/0001213900-25-068745.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.